Skip to main content

Accelr8 Reports Preliminary FY2010 Revenues of $2.2M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 Technology today reported preliminary revenues of $2.2 million for its fiscal year ended July 31, compared to revenues of $1.3 million for FY 2009.

The Denver-based firm also reported net income of $650,447 for the year, compared to a net loss of $714,197 for the previous year.

Accelr8 also noted that its total shareholders' equity was approximately $4.9 million. Last month, the firm had been notified by the NYSE Amex that it was still not in compliance with listing standards. In order to be listed, the exchange requires that a company have at least $4 million in stockholder equity if it has losses from continuing operations and net losses in three of the four most recent fiscal years.

In early Thursday trade, shares of Accelr8 were up 12 percent at $.90.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.